Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 200, 72-80
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province
- Suzhou Key Medical Center
- National Natural Science Foundation of China
- Suzhou Municipal Science and Technology Bureau
This publication has 26 references indexed in Scilit:
- Novel platelet activation receptor CLEC‐2: from discovery to prospectsJournal of Thrombosis and Haemostasis, 2011
- Contribution of platelets to tumour metastasisNature Reviews Cancer, 2011
- CLEC-2 activates Syk through dimerizationBlood, 2010
- Assessing Risk of Venous Thromboembolism in the Patient With CancerJournal of Clinical Oncology, 2009
- Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC‐2Journal of Thrombosis and Haemostasis, 2008
- High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)Blood, 2008
- The C-type Lectin Receptors CLEC-2 and Dectin-1, but Not DC-SIGN, Signal via a Novel YXXL-dependent Signaling CascadeJournal of Biological Chemistry, 2007
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007
- A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2Blood, 2006
- Platelets and cancerThe Lancet Oncology, 2002